The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study
Open accessPublished version of a preprint
Abstract
An effective vaccine is needed to end the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Here, we assess the preliminary safety, tolerability and immunogenicity data from an ongoing single-center (in Jiangsu province, China), parallel-group, double-blind phase 1 trial of the vaccine candidate BNT162b1 in 144 healthy SARS-CoV-2-naive Chinese participants. These participants are randomized 1:1:1 to receive prime and boost vaccinations of 10 µg or 30 µg BNT162b1 or placebo, given 21 d apart, with equal allocation of younger (aged 18-55 years) and older adults (aged 65-85 years) to each treatment group (ChiCTR2000034825). BNT162b1 encodes the SARS-CoV-2 spike glycoprotein receptor-binding domain (RBD) and is one of several messenger RNA-based vaccine candidates under clinical investigation. Local reactions and systemic events were generally dose dependent, transient and mild to moderate. Fever was the only grade 3 adverse event. BNT162b1 induced robust interferon-γ T cell responses to a peptide pool including the RBD in both younger and older Chinese adults, and geometric mean neutralizing titers reached 2.1-fold (for younger participants) and 1.3-fold (for the older participants) that of a panel of COVID-19 convalescent human sera obtained at least 14 d after positive SARS-CoV-2 polymerase chain reaction test. In summary, BNT162b1 has an acceptable safety profile and produces high levels of humoral and T cell responses in an Asian population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a randomized phase I study on BNT162b1 in younger (18-55 years) and older adults (65-85 years), virus neutralization was lower in the older age group 22 days after the first dose 20 .”
From Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 (2021) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, the incidence of grade 3 fever of ARCoV was similar to the trial results of another RBD-based mRNA vaccine, BNT162b1.16”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In phase 1 trials, mRNA-based vaccines (ARCoV, BNT162b1)16 and adenovirus-vector vaccines (ChAdOx1,25 Ad5 vectored COVID-19 vaccine)26 induced a strong T-helper-1-cell response in most participants.”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The incidence of grade 3 fever of BNT162b1 varied significantly in the same 30 μg group in adults aged 18–55 years, with none (0%) of 12 in the USA,17 one (8%) of 12 in Germany,18 and four (17%) of 24 in China,16 suggesting varying tolerability in different populations.”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [16]
In the citing paper
“Till now, all of these candidates have entered clinical trials (Table 5).130,376,377”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [377]
In the citing paper
“BioNTech and Pfizer collaborated to develop five COVID-19 mRNA vaccine candidates at the beginning of the pandemic, which were based on nucleoside-modified mRNA (BNT162b2, BNT162b1, BNT162b3), non-modified mRNA (BNT162a1) and self-amplifying mRNA (BNT162c2).”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [377]
In the citing paper
“acceptable safety profile and high levels of humoral and T cell responses in younger (ages 18–55 years) and older adults (ages 65–85 years) in an Asian population83”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Self-citationCOVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Self-citation
Research works printed but not linked: 2
- Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020). · DOI · Paper page
- Mulligan, M. J. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589–593 (2020). · DOI · Paper page
Cited by
Sorted by citations
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
Collier, D. A., Ferreira, I. A. T. M., Kotagiri, P., Datir, R. P., Lim, E. Y., Touizer, E., Meng, B., Abdullahi, A., The CITIID-NIHR BioResource COVID-19 Collaboration, Principal Investigators, et al. (2021) · Nature · doi:10.1038/s41586-021-03739-1 · Cited by 751
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Efficacy and safety of COVID-19 vaccines
Graña, C., Ghosn, L., Evrenoglou, T., Jarde, A., Minozzi, S., Bergman, H., Buckley, B. S., Probyn, K., Villanueva, G., Henschke, N., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015477 · Cited by 310
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308
Nanotechnology-based mRNA vaccines
Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 177
Self-citationFrequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials
Haas, J. W., Bender, F. L., Ballou, S., Kelley, J. M., Wilhelm, M., Miller, F. G., Rief, W., & Kaptchuk, T. J. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.43955 · Cited by 161
Sauré, D., O’Ryan, M., Torres, J. P., Zuniga, M., Santelices, E., & Basso, L. J. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00479-5 · Cited by 147
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
Kleanthous, H., Silverman, J. M., Makar, K. W., Yoon, I.-K., Jackson, N. M., & Vaughn, D. W. (2021) · npj Vaccines · doi:10.1038/s41541-021-00393-6 · Cited by 139
Tan, A. T., Lim, J. M. E., Bert, N. L., Kunasegaran, K., Chia, A., Qui, M., Tan, N., Chia, W. N., de Alwis, R., Ying, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152379 · Cited by 110
Host factors and vaccine efficacy: Implications for COVID‐19 vaccines
Falahi, S., & Kenarkoohi, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27485 · Cited by 105
Zhang, J., He, Q., An, C., Mao, Q., Gao, F., Bian, L., Xing, W., Wang, Q., Liu, P., Song, L., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1957401 · Cited by 95
Marasco, V., Carniti, C., Guidetti, A., Farina, L., Magni, M., Miceli, R., Calabretta, L., Verderio, P., Ljevar, S., Serpenti, F., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17877 · Cited by 94
A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines
Ghasemiyeh, P., Mohammadi‐Samani, S., Firouzabadi, N., Dehshahri, A., & Vazin, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108162 · Cited by 100
A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues
Khandker, S. S., Godman, B., Jawad, M. I., Meghla, B. A., Tisha, T. A., Khondoker, M. U., Haq, M. A., Charan, J., Talukder, A. A., Azmuda, N., et al. (2021) · Vaccines · doi:10.3390/vaccines9121387 · Cited by 88
Chen, G.-L., Li, X.-F., Dai, X.-H., Li, N., Cheng, M.-L., Huang, Z., Shen, J., Ge, Y.-H., Shen, Z.-W., Deng, Y.-Q., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00280-9 · Cited by 82
Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects
Huang, T., Peng, L., Han, Y., Wang, D., He, X., Wang, J., & Ou, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.922301 · Cited by 87
Advances in the design and development of SARS-CoV-2 vaccines
Peng, X., Cheng, J., Gong, H., Yuan, M.-D., Zhao, X., Li, Z., & Wei, D. (2021) · Military Medical Research · doi:10.1186/s40779-021-00360-1 · Cited by 84
Xu, K., Wang, Z., Qin, M., Gao, Y., Luo, N., Xie, W., Zou, Y., Wang, J., & Ma, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113156 · Cited by 83
Mechanisms underpinning poor antibody responses to vaccines in ageing
Lee, J. L., & Linterman, M. A. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.11.001 · Cited by 73
Demaret, J., Corroyer-Simovic, B., Alidjinou, E. K., Goffard, A., Trauet, J., Miczek, S., Vuotto, F., Dendooven, A., Huvent‐Grelle, D., Podvin, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.778679 · Cited by 70
Rénia, L., Goh, Y. S., Rouers, A., Bert, N. L., Chia, W. N., Chavatte, J., Fong, S., Chang, Z. W., Zhuo, N. Z., Tay, M. Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32312-1 · Cited by 62
Targeting strategies for mRNA delivery
Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 55
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Rocha, V. P. C., Soares, M. B. P., Berglund, P., Duthie, M. S., Reed, S. G., et al. (2021) · Vaccines · doi:10.3390/vaccines9111345 · Cited by 55
Lee, H., Knabl, L., Moliva, J. I., Knabl, L., Werner, A. P., Boyoglu-Barnum, S., Kapferer, S., Pateter, B., Walter, M., Sullivan, N. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110680 · Cited by 47
Xu, K., Dai, L., & Gao, G. F. (2021) · International Immunology · doi:10.1093/intimm/dxab061 · Cited by 48
Woo, W., Kim, A. Y., Yon, D. K., Lee, S. W., Hwang, J., Jacob, L., Koyanagi, A., Kim, M. S., Moon, D. H., Jung, J. W., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27501 · Cited by 50
Jin, P., Guo, X., Chen, W., Ma, S.-H., Pan, H., Dai, L., Du, P., Wang, L., Jin, L., Chen, Y., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003953 · Cited by 46
Self-citationSaggau, C., Martini, G. R., Rosati, E., Meise, S., Messner, B., Kamps, A.-K., Bekel, N., Gigla, J. B., Rose, R., Voß, M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.003 · Cited by 42
Myocarditis following mRNA vaccination against SARS-CoV-2, a case series
King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Pardo, L. C., & Petersen, J. W. (2021) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2021.100042 · Cited by 38
SFTSV Gn‐Head mRNA vaccine confers efficient protection against lethal viral challenge
Kim, D.-K., Lai, C., Cha, I., Kang, S., Yang, W., Choi, Y., & Jung, J. U. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29203 · Cited by 39
Zhu, L., Xu, X. P., Zhu, B., Guo, X., Xu, K., Song, C., Fu, J., Yu, H., Kong, X., Peng, J., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00590-21 · Cited by 38
Self-citationEfficacy and safety of COVID‐19 vaccines: A network meta‐analysis
Toubasi, A. A., Al-Sayegh, T., Obaid, Y. Y., Al‐Harasis, S. M., & AlRyalat, S. A. (2022) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12492 · Cited by 37
Li, Z., Liu, S., Li, F., Li, Y., Li, Y., Peng, P., Li, S., Li, H., & Liu, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965971 · Cited by 40
A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines
Ashmawy, R., Hamdy, N. A., Elhadi, Y. A. M., Alqutub, S. T., Esmail, O. F., Abdou, M. S. M., Reyad, O. A., El-Ganainy, S. O., Gad, B. K., El-Deen, A. E.-S. N., et al. (2022) · Journal of Primary Care & Community Health · doi:10.1177/21501319221089255 · Cited by 35
Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine
Wu, Y., Wang, S., Zhang, Y., Yuan, L., Zheng, Q., Wei, M., Shi, Y., Wang, Z., Ma, J., Wang, K., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.011 · Cited by 35
Self-citationSafety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review.
SeyedAlinaghi, S., Karimi, A., Pashaei, Z., Afzalian, A., Mirzapour, P., Ghorbanzadeh, K., Ghasemzadeh, A., Dashti, M., Nazarian, N., Vahedi, F., et al. (2022) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v10i1.1597 · Cited by 33
Lee, J. L., Fra-Bidó, S., Burton, A. R., Innocentin, S., Hill, D. L., & Linterman, M. A. (2022) · Aging Cell · doi:10.1111/acel.13692 · Cited by 34
Recent developments in SARS‐CoV‐2 vaccines: A systematic review of the current studies
Sadeghalvad, M., Mansourabadi, A. H., Noori, M., Nejadghaderi, S. A., Masoomikarimi, M., Alimohammadi, M., & Rezaei, N. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2359 · Cited by 35
Dhumal, S. B., Patil, A., More, A. N., Kamtalwar, S., Joshi, A. D., Gokarn, A. G., Mirgh, S. P., Thatikonda, P., Bhat, P., Murthy, V., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.02.037 · Cited by 27
Geriatric Health Care During the COVID-19 Pandemic: Managing the Health Crisis
Zhu, Y., Liu, Y., & Jiang, H. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s376519 · Cited by 29
Sharun, K., Singh, R. P., & Dhama, K. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102264 · Cited by 28
What Happens to the Immune System after Vaccination or Recovery from COVID-19?
Tiyo, B. T., Schmitz, G. J. H., Ortega, M. M., da Silva, L. T., de Almeida, A., Oshiro, T. M., & Duarte, A. J. D. S. (2021) · Life · doi:10.3390/life11111152 · Cited by 28
Roles of RNA-binding proteins in neurological disorders, COVID-19, and cancer
Sanya, D. R. A., Cava, C., & Onésime, D. (2022) · Human Cell · doi:10.1007/s13577-022-00843-w · Cited by 26
Efficacy and Safety of COVID-19 Vaccination in Older Adults: A Systematic Review and Meta-Analysis
Zhang, L., Jiang, L., Tian, T., Li, W., Pan, Y., & Wang, Y. (2022) · Vaccines · doi:10.3390/vaccines11010033 · Cited by 28
Rudan, I., Adeloye, D., Katikireddi, S. V., Murray, J., Simpson, C. R., Shah, S. A., Robertson, C., & Sheikh, A. (2021) · Journal of Global Health · doi:10.7189/jogh.11.01011 · Cited by 24
SARS-CoV-2 immunity and vaccine strategies in people with HIV
Mullender, C., da Costa, K., Alrubayyi, A., Pett, S. L., & Peppa, D. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac005 · Cited by 23
de Medeiros, G. X., Sasahara, G. L., Magawa, J. Y., Nunes, J. P. S., Bruno, F. R., Kuramoto, A., Almeida, R. R., Ferreira, M. A., Scagion, G. P., Candido, E. D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.812126 · Cited by 23
Gui, Y., Li, X., Li, J., Shen, M., Zhang, M., Cao, Y., Xu, H., Li, H., Cheng, J., Pan, L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104586 · Cited by 21
Self-citationSuzuki, M., Sekiguchi, Y., Sasaki, M., Inaba, S., Oyama, S., Inoue, Y., Warabi, M., Ohashi, K., & Inoshita, S. (2022) · Internal Medicine · doi:10.2169/internalmedicine.9807-22 · Cited by 21
Influenza Virus and SARS-CoV-2 Vaccines
Sandor, A., Sturdivant, M. S., & Ting, J. P. ‐. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001287 · Cited by 23
Masuda, T., Murakami, K., Sugiura, K., Sakui, S., Schuring, R. P., & Mori, M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.035 · Cited by 19
Jergović, M., Uhrlaub, J. L., Watanabe, M., Bradshaw, C. M., White, L. M., LaFleur, B., Edwards, T., Sprissler, R. S., Worobey, M., Bhattacharya, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30617-9 · Cited by 21
van den Ouweland, F., Charpentier, N., Türeci, Ö., Rizzi, R., Mensa, F., Lindemann, C., & Pather, S. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2315659 · Cited by 20
Self-citationPortilho, A. I., Lima, G. G., & Gaspari, E. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061503 · Cited by 19
Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study
Duan, Y., Luo, J., Zhao, L., Zhang, X., Miao, J., Moher, D., & Bian, Z. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103962 · Cited by 18
Self-citationKuse, N., Zhang, Y., Chikata, T., Nguyen, H. T., Oka, S., Gatanaga, H., & Takiguchi, M. (2022) · Nature Communications · doi:10.1038/s41467-022-32989-4 · Cited by 17
Fidler, S. J., Fox, J., Tipoe, T., Longet, S., Tipton, T., Abeywickrema, M., Adele, S., Alagaratnam, J., Ali, M., Aley, P. K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac796 · Cited by 17
Herpetic Eye Disease Following the SARS-CoV-2 Vaccinations
Cohen, S., Olshaker, H., Fischer, N., Vishnevskia‐Dai, V., Hagin, D., Rosenblatt, A., Zur, D., & Habot‐Wilner, Z. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2103831 · Cited by 15
Circular mRNA Vaccine against SARS-COV-2 Variants Enabled by Degradable Lipid Nanoparticles
Huang, K., Li, N., Li, Y., Zhu, J., Fan, Q., Yang, J., Gao, Y., Liu, Y., Gao, S., Zhao, P., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c20770 · Cited by 32
Hui, A., Li, J., Zhu, L., Tang, R., Ye, H., Lin, M., Ge, L., Wang, X., Peng, F., Wu, Z., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100586 · Cited by 19
Self-citationDelivery of Circular mRNA via Degradable Lipid Nanoparticles against SARS-CoV-2 Delta VariantPreprint
Huang, K., Li, N., Li, Y., Zhu, J., Fan, Q., Yang, J., Gao, Y., Liu, Y., Hou, Q., Gao, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.12.491597 · Cited by 16
Hwang, N., Huh, Y., Bu, S., Seo, K. J., Kwon, S. H., Kim, J. W., Yoon, B. K., Ahn, H., & Fang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.979188 · Cited by 16
Rudan, I., Millington, T., Antal, K., Grange, Z., Fenton, L., Sullivan, C. B., Buelo, A., Wood, R., Woolford, L., Swann, O. V., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100513 · Cited by 15
Yao, L., Wu, L., Wang, R., Liu, Y., Luo, F., Zhang, Y., & Chen, G. (2022) · ACS Macro Letters · doi:10.1021/acsmacrolett.2c00291 · Cited by 14
Yang, B., Huang, X., Gao, H., Leung, N., Tsang, T. K., & Cowling, B. J. (2022) · BMC Medicine · doi:10.1186/s12916-022-02600-0 · Cited by 14
Clavero, R., Parra-Lucares, A., Méndez-Valdés, G., Villa, E., Bravo, K., Mondaca, E., Aranda, J., Brignardello, R., Gajardo, C., Ordenes, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10091542 · Cited by 13
Wang, T., Yu, T., Li, W., Chen, J., Cheng, S., Tian, Z., Sung, T., & Higuchi, A. (2025) · Regenerative Biomaterials · doi:10.1093/rb/rbaf023 · Cited by 15
Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection
Jiang, X., Song, X., Shi, C., Yang, G., Wang, X., Zhang, Y.-W., Wu, J., Zhao, L., Zhang, M., Wang, M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114387 · Cited by 13
Hyun, Y., Lee, Y., Jo, H.-A., Baek, I., Kim, S.-M., Sohn, H., & Kim, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.774491 · Cited by 11
Blanquart, F., Abad, C., Ambroise, J., Bernard, M., Débarre, F., Giannoli, J., Rey, T., & Vieillefond, V. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.04.410 · Cited by 13
Yuniar, C. T., Pratiwi, B., Ihsan, A. F., Laksono, B. T., Risfayanti, I., Fathadina, A., Jeong, Y., & Kim, E. Y. (2022) · Vaccines · doi:10.3390/vaccines10020313 · Cited by 13
Colucci, M., Santis, E. D., Totti, B., Miroballo, M., Tamiro, F., Rossi, G., Piepoli, A., Vincentis, G. D., Greco, A., Mangia, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9101207 · Cited by 10
Ríos, S. S., Zamora, E. B. C., Céspedes, A. A., Rizos, L. R., Sánchez‐Jurado, P. M., Nievas, G. S., Romero, M. M., Sahuquillo, M. T. T., Señalada, J. J. B., Romero, A. M., et al. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17620 · Cited by 10
Lau, O., & Vadlamudi, N. K. (2021) · Value in Health · doi:10.1016/j.jval.2021.09.003 · Cited by 10
Panahi, Y., Einollahi, B., Beiraghdar, F., Darvishi, M., Fathi, S., Javanbakht, M., Shafiee, S., & Akhavan‐Sigari, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947602 · Cited by 10
Chen, G., Qiu, Y., Wu, K., Wu, Y., Wang, Y., Zou, Y.-Y., Peng, C., Zhao, J., Su, C., Ma, J.-H., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2285089 · Cited by 9
Self-citationJahrsdörfer, B., Fabricius, D., Scholz, J. A. M., Ludwig, C., Grempels, A., Lotfi, R., Körper, S., Adler, G., & Schrezenmeier, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.743422 · Cited by 10
mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic
Chen, P., Shi, X., He, W., Zhong, G., Tang, Y., Wang, H., & Zhang, P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2040330 · Cited by 10
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
Kim, E., Khan, M. S., Ferrari, A., Huang, S., Sammartino, J. C., Percivalle, E., Kenniston, T. W., Cassaniti, I., Baldanti, F., & Gambotto, A. A. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04363-22 · Cited by 10
Acute myocarditis following COVID-19 mRNA vaccination: a paediatric case
Giray, D., & Epçaçan, S. (2022) · Cardiology in the Young · doi:10.1017/s1047951121004698 · Cited by 8
Waits, A., Chen, J., Cheng, W.-H., Yeh, J., Hsieh, S., Chen, C., Janssen, R. S., Lien, C.-E., & Lin, T. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.08.021 · Cited by 8
COVID-19 Vaccination in Children: An Open Question
Bardanzellu, F., Campagnani, G., Pintus, M. C., Fanos, V., & Marcialis, M. A. (2021) · Current Pediatric Reviews · doi:10.2174/1573396318666211220093111 · Cited by 8
Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm
Abusalah, M. A. H., Khalifa, M., Al-Hatamleh, M. A. I., Jarrar, M., Mohamud, R., & Yean, C. Y. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030386 · Cited by 6
Li, J., Hui, A., Zhang, X., Ge, L., Qiu, Y., Tang, R., Ye, H., Wang, X., Lin, M., Zhu, Z., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02206-1 · Cited by 7
Self-citationKutikuppala, L. V. S., Kandi, V., Sarangi, A. K., Mishra, S., & Mohapatra, R. K. (2022) · Geriatrics · doi:10.3390/geriatrics7060143 · Cited by 7
Dogra, N., Ledesma‐Feliciano, C., & Sen, R. (2021) · Journal of Developmental Biology · doi:10.3390/jdb9040054 · Cited by 7
Debnath, S. K., & Srivastava, R. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2021.813847 · Cited by 7
Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
Chen, G., Yu, X., Luo, L., Zhang, F., Dai, X.-H., Li, N., Shen, Z.-W., Wu, K.-Q., Lou, D., Peng, C.-G., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.065 · Cited by 6
Micronanoparticled risedronate exhibits potent vaccine adjuvant effects
Nie, M., Wu, S., Chen, Y., Wu, Y., Chen, R., Liu, Y., Yue, M., Jiang, Y., Qiu, D., Yang, M., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.025 · Cited by 6
Pawar, S., Pingale, P., Garkal, A., Osmani, R. A. M., Gajbhiye, K. R., Kulkarni, M., Pardeshi, K., Mehta, T. A., & Rajput, A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131139 · Cited by 6
Multifunctional Dendronized Polypeptides for Controlled Adjuvanticity
Fan, Z., Jan, S., Hickey, J. C., Davies, D. H., Felgner, J. H., Felgner, P. L., & Guan, Z. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c01052 · Cited by 6
Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis
Yang, I., Lu, C., Tang, H.-J., Kuo, Y.-C., Tsai, L.-H., Tu, K.-C., Wang, J., & Chien, C.-C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273676 · Cited by 6
Gui, Y., Cao, Y., He, J., Zhao, C., Zheng, W., Qian, L., Cheng, J., Yu, C., Chen, Y., Lou, K., et al. (2023) · Life Metabolism · doi:10.1093/lifemeta/load019 · Cited by 6
Global research on RNA vaccines for COVID-19 from 2019 to 2023: a bibliometric analysis
Chen, Z., Liu, Z., Feng, Y., Shi, A., Wu, L., Sang, Y., & Li, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1259788 · Cited by 7
Liu, J., Li, Z., Qiong, K., Liu, Q., Sun, Y., Yan, R., Ye, H., Zhang, Y., Ren, J., Chen, H., et al. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01381-9 · Cited by 4
Self-citationLin, X., Li, A.-L., Zhang, M., Lv, L., Chen, Y., Chen, H.-D., Tung, T., & Zhu, J. (2022) · Vaccines · doi:10.3390/vaccines10101665 · Cited by 4
Holtkamp, C., Schöler, L., Anastasiou, O. E., Brune, B., Fessmann, K., Elsner, C., Möhlendick, B., Čiučiulkaitė, I., Dudda, M., Trilling, M., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12746 · Cited by 4
Mirzakhani, M., Bayat, M., Dashti, M., Tahmasebi, S., Rostamtabar, M., Ghaleh, H. E. G., & Amani, J. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2579 · Cited by 5
Gu, Y., Shunmuganathan, B. D. O., Qian, X., Gupta, R., Tan, R. S. W., Kozma, M., Purushotorman, K., Murali, T. M., Tan, N. Y., Preiser, P. R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-49231-w · Cited by 8
Self-citationBouchlarhem, A., Boulouiz, S., Bazid, Z., Ismaili, N., & Ouafi, N. E. (2024) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468231221406 · Cited by 5
Metadata
- Authors
- Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., Ji, R., Lin, M., Zhu, Z., Türeci, Ö., Lagkadinou, E., Jia, S., Pan, H., Peng, F., Ma, Z., Wu, Z., Guo, X., Shi, Y., Muik, A., Şahin, U., Zhu, L., & Zhu, F.
- Affiliations
- Jiangsu Provincial Center for Disease Control and Prevention (CN)
- Fosun Pharma (China) (CN)
- Army Medical University (CN)
- The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN)
- BioNTech (Germany) (DE)
- Corresponding author
- Zhu, Li
- Zhu, Fengcai
- ORCID
- Venue
- Nature Medicine
- Published
- 2021-04-22
- Volume
- 27
- Issue
- 6
- Pages
- 1062-1070
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W3154648093
- Cited by
- 133
- References
- 25
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 7 · 2023: 16 · 2022: 65 · 2021: 33
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature Medicine (publishedVersion)
- Research Square (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- mRNA vaccines, SARS-CoV-2, COVID-19 vaccines, vaccine safety, immunogenicity, older adults, young adults, spike protein receptor-binding domain, neutralizing antibodies, dose comparison, adverse events, Chinese adults
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, China, Female, Humans, Male, Middle Aged, RNA, Messenger, Vaccines, Synthetic, Young Adult, Antibodies, Neutralizing, Pandemics, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
